MedTrace Logo

Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19

NCT04712357 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2021-01-15

No results posted yet for this study

Summary

Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19

Conditions

  • Covid19

Interventions

DRUG

Vitamin C 500 MG Oral Tablet

Vitamin C 500 MG per day for 10 days

DRUG

Tenofovir disoproxyl fumarate 300 MG Oral Tablet

Tenofovir disoproxyl fumarate 300 MG per day for 10 days

DRUG

Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet

Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days

Sponsors & Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

    collaborator OTHER_GOV

  • São José Hospital for Infectious Diseases - HSJ

    collaborator UNKNOWN

  • Central Laboratory of Public Health of Ceará - Lacen-CE

    collaborator UNKNOWN

  • Universidade Federal do Ceara

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2022-01-31
Completion
2023-01-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04712357 on ClinicalTrials.gov